An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)
Status: Recruiting
Location: See all (6) locations...
Study Type: Observational
SUMMARY
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
• Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
• Frequent premature ventricular contractions (PVCs)
• Patients must have an ICD placed prior to enrollment
• Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.
Locations
United States
California
Leland Stanford Junior University
RECRUITING
Redwood City
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Northshore University Healthsystem Research Institute
RECRUITING
Columbia
Michigan
University of Michigan
RECRUITING
Ann Arbor
Henry Ford Hospital
RECRUITING
Detroit
New York
University of Rochester
RECRUITING
Rochester
Contact Information
Primary
Person*: Lexeo Clinical Trials
clinicaltrials@lexeotx.com
212-547-9879
Time Frame
Start Date: 2024-01-23
Estimated Completion Date: 2027-09
Participants
Target number of participants: 40
Related Therapeutic Areas
Sponsors
Leads: Lexeo Therapeutics